Evidence map›Paper›PMID 32435754›Full record

ArticleJHEP reports : innovation in hepatology2020

Health-related quality of life and patient-reported outcome measures in NASH-related cirrhosis.

Lorraine McSweeney, Matthew Breckons, Gulnar Fattakhova, Yemi Oluboyede, Luke Vale, Laura Ternent, Maria-Magdalena Balp, Lynda Doward, Clifford A Brass, Fiona Beyer and 2 more

Open access · goldAbstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 3 pooled it
5.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. MASLD as a non-communicable disease.Nature reviews. Gastroenterology & hepatology · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Advancing the global public health agenda for NAFLD: a consensus statement.Nature reviews. Gastroenterology & hepatology · 2022
    Review
  17. What's new in non-alcoholic fatty liver disease?Frontline gastroenterology · 2022
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Lorraine McSweeneyPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Matthew BreckonsPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Gulnar FattakhovaPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Yemi OluboyedePopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Luke ValePopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Laura TernentPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Maria-Magdalena BalpNovartis Pharma AG, Basel, Switzerland.
Lynda DowardRTI-Health Solutions, The Pavilion, Towers Business Park, Wilmslow Road, Didsbury, Manchester, UK.
Clifford A BrassNovartis Pharmaceutical Corporation, East Hanover, United States.
Fiona BeyerPopulation Health Sciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Arun SanyalDivision of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, United States.
Quentin M AnsteeTranslational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK & Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK.
Newcastle University · GBNIHR Newcastle Biomedical Research Centre · GBNovartis (Switzerland) · CHNovartis (United States) · USVirginia Commonwealth University · US

Funding

Medical Research Council MR/K02325X/1
6 · The paper itself

Abstract

BACKGROUND &

aimsNon-alcoholic steatohepatitis (NASH) is known to have a negative impact on patients' health-related quality of life (HRQoL), even before progression to cirrhosis has occurred. The burden of NASH-related cirrhosis from the patient perspective remains poorly understood. Herein, we aimed to identify the burden of disease and HRQoL impairment among patients with NASH-related compensated cirrhosis.

methodsThis targeted literature review sought first to identify the humanistic burden of disease from the perspective of patients with diagnosed NASH-cirrhosis and, secondly, to identify generic or disease-specific patient-reported outcome measures (PROMs) used to assess the impact of NASH-cirrhosis. Searches were conducted in bibliographical databases, grey or unpublished literature, liver disease websites, support group websites and online blogs. A quality assessment of specific PROMs was conducted.

resultsPatients with NASH-cirrhosis are reported to suffer from lower HRQoL than patients with non-cirrhotic NASH and the general population with respect to physical health/functioning, emotional health and worry, and mental health. Thirteen PROMs were identified, of which 4 were liver-disease specific: CLDQ, CLDQ-NAFLD, LDQoL and LDSI. The most commonly used measures do not comply with current industry or regulatory standards for PROMs and/or are not validated for use in a cirrhotic NASH population.

conclusionsPatients with NASH-cirrhosis have lower HRQoL and poorer physical health than patients with non-cirrhotic NASH. However, the literature lacked detail of the everyday impact on patients' lives. Currently, a number of PROMs are available to measure the impact of the disease in patients with chronic liver conditions. The lack of studies that include qualitative insights in this population mandates further exploration and research. LAY SUMMARY: It is not well understood how having non-alcoholic fatty liver disease (NAFLD)-related cirrhosis affects a person's everyday wellbeing and quality of life. Some research has been done with patients who have early stages of liver disease but not people with cirrhosis. We found that patients with NAFLD-related cirrhosis tended to have poorer health than patients without cirrhosis. But there was not very much information from patients themselves and there were no tools or questionnaires just for this group of patients.

Indexed as

CirrhosisCLDQ, chronic liver disease questionnaireCOSMIN, The COnsensus-based Standards for the selection of health Measurement INstrumentsEMA, European Medicines AgencyFDA, United States Food and Drug AdministrationFIS, fatigue impact scalehealth-related quality of lifeHRQoL, health-related quality of lifeLDQoL, liver disease quality of life questionnaireLDSI, liver disease symptom indexliverMS, multiple sclerosisNAFLDNAFLD, non-alcoholic fatty liver diseaseNAFL, non-alcoholic fatty liverNASH, non-alcoholic steatohepatitisNon-alcoholic steatohepatitispatient-reported outcome measuresPHAQ, patient-reported outcome measurement information system health assessment questionnairePROM, patient-reported outcome measurePRO, patient-reported outcomeQoL, quality of lifeRI, researcher interpretationSF-36, short form health profile 36

Identifiers

PMID32435754
PMCPMC7229498
OpenAlexW3009253119

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.